Clinical Trial Update: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating dasatinib in combination with quercetin to overcome chemotherapy resistance in triple-negative breast cancer. The study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• DASATINIB (Dasatinib)
• Quercetin (quercetin)

Snippet

Sponsor: Fudan University | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: RECRUITING